ANIK
Anika Therapeutics Inc.

639
Mkt Cap
$139.13M
Volume
43,969.00
52W High
$25.00
52W Low
$7.87
PE Ratio
-2.33
ANIK Fundamentals
Price
$9.68
Prev Close
$9.65
Open
$9.75
50D MA
$9.07
Beta
0.93
Avg. Volume
102,301.19
EPS (Annual)
-$3.83
P/B
0.94
Rev/Employee
$416,343.75
Loading...
Loading...
News
all
press releases
Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains?
Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Wall Street Analysts See a 98.59% Upside in Anika (ANIK): Can the Stock Really Move This High?
The consensus price target hints at a 98.6% upside potential for Anika (ANIK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·2mo ago
News Placeholder
Anika (ANIK) Upgraded to Buy: Here's What You Should Know
Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·2mo ago
News Placeholder
Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates
Anika (ANIK) delivered earnings and revenue surprises of 0.00% and +4.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of +22.47% and -26.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock?
Recursion Pharmaceuticals (RXRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·3mo ago
News Placeholder
Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates
chainwire·6mo ago
News Placeholder
Retail Investors Remain Cautious After Anika’s Q3 Earnings Misses Estimates
Barrington analyst Michael Petusky has cut the firm’s price target to $25 from $37
Stocktwits·1y ago
News Placeholder
Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics
Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics PR Newswire WEST BRIDGEWATER, Mass...
PR Newswire·1y ago
News Placeholder
Peeling Back The Layers: Exploring Anika Therapeutics Through Analyst Insights
Latest Ratings for ANIK DateFirmActionFromTo Mar 2022Stephens & Co.DowngradesOverweightEqual-Weight Nov 2021Stephens & Co.Initiates Coverage OnOverweight Jul 2021UBSInitiates Coverage OnNeutral...
Benzinga·1y ago

Latest ANIK News

View

Advertisement|Remove ads.

Advertisement|Remove ads.